Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 1.00 |
| ▸ | TGFBR2 | P37173 | 2/20 | 1.00 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18041895 | 1.00 | TGFBR1 (1.00) | TGFBR1TGFBR2NSD3DYRK1A | |
| SCHEMBL13680666 | 0.82 | TGFBR1 (0.68) | TGFBR1TGFBR2DYRK1A | |
| SCHEMBL18041777 | 0.79 | TGFBR1 (1.00) | TGFBR1TGFBR2 | |
| SCHEMBL15638648 | 0.79 | TGFBR1 (0.65) | TGFBR1TGFBR2DYRK1A | |
| SCHEMBL18041609 | 0.76 | TGFBR1 (0.61) | TGFBR1TGFBR2DYRK1A | |
| SCHEMBL17767477 | 0.76 | TGFBR1 (0.61) | TGFBR1TGFBR2DYRK1A | |
| SCHEMBL18041724 | 0.75 | TGFBR1 (1.00) | TGFBR1TGFBR2NSD3 | |
| SCHEMBL29676949 | 0.75 | TGFBR1 (1.00) | TGFBR1TGFBR2NSD3 | |
| SCHEMBL17767480 | 0.75 | TGFBR1 (0.60) | TGFBR1TGFBR2DYRK1A | |
| SCHEMBL18057147 | 0.74 | TGFBR1 (0.58) | TGFBR1TGFBR2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885TGFBR2 2/4885NSD3 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.